On December 9, 2023, the Shanghai Diabetes Advanced Technology and Technology Forum (hereinafter referred to as SATTD) was successfully held in Shanghai, sponsored by Zhongguancun Precision Medicine Association, Shanghai Biomedical Engineering Society, Shanghai Diet Therapy Research Association, and Beijing Association for the Prevention and Treatment of Chronic Diseases of Traditional Chinese and Western Medicine, undertaken by Shanghai Public Health Clinical Center, and co-organized by the Metabolic Medical Engineering Professional Committee of Shanghai Biomedical Engineering Society, and Blood Glucose Monitoring and New Technology Group of Diabetes Branch of Shanghai Medical Association.
The 2nd Shanghai Diabetes Advanced Technology and ** Forum opened).
As a highly authoritative event that brings together advanced technologies and concepts of diabetes, this conference attracted nearly 1,000 physicians, enterprise R&D personnel, chronic disease service providers and capital investors from all over the country to conduct in-depth exchanges on topics such as new technologies, new concepts in the field of diabetes and the ecological construction of digital diabetes care. Dr. Peng Can, Chief Scientific Officer of Silicon-based Bionics, was invited to attend this forum to share the latest research progress of artificial pancreas intelligent closed-loop algorithms, and to contribute to the joint development of the field of diabetes.
The future is here: intelligent closed-loop algorithms help fully closed-loop artificial pancreas.
In order to achieve the goal of "technology makes diabetes patients better" and make advanced glucose monitoring and pump technology benefit more diabetic patients, the Shanghai Diabetes Advanced Technology and Pump Forum (SATTD) has been committed to the exploration and promotion of advanced diabetes technology. At this SATTD conference, many medical experts and product R&D teams have focused on the new application value brought by the exploration of CGM technology - the closed-loop management of diabetes and the realization of artificial pancreas.
As a leading enterprise in China's CGM industry, Silicon-based Bionic has deep insights in the field of artificial pancreatic intelligent closed-loop algorithms, and its Chief Scientific Officer Dr. Peng Can shared the latest achievements of silicon-based bionic in artificial pancreas intelligent closed-loop algorithms at the theme satellite conference of "The Future Has Come, Progress in the Development of Intelligent Closed-loop Algorithms", and looked forward to the great help that this technology will bring to diabetic patients. As Dr. Peng said, "With the continuous maturity and popularization of continuous glucose monitoring system (CGM) and continuous insulin infusion system, the closed-loop artificial pancreas system can simulate the physiological secretion pattern of human insulin to the greatest extent, and is an insulin** way to achieve effective glucose control." In order to achieve the design goal of the closed-loop artificial pancreas system to minimize or prevent short- and long-term complications of diabetes and reduce the daily burden of diabetes management, intelligent closed-loop algorithms have become a top priority. ”
Dr. Peng Can shared the research and development progress of intelligent closed-loop algorithms).
In July 2022, Silicon-based Bionic established Shandong Silicon-based Computing Technology Co., Ltd. in Jinan, Shandong Province, focusing on the digital field of diabetes, giving full play to its cutting-edge advantages and technology accumulation in medical artificial intelligence, and committed to developing artificial pancreas intelligent closed-loop algorithms with independent intellectual property rights, realizing domestic independent guarantees, filling domestic gaps, and actively promoting the application of "full closed-loop artificial pancreas" to help the development of the diabetes digital industry.
Popularizing continuous glucose monitoring technology: creating a digital closed loop for blood glucose management.
The silicon-based dynamic dynamic glucose meter launched by Silicon-based Bionic is the second CGM product in the world and the first in China to adopt the principle of the second-generation glucose sensor, and it is also the first continuous glucose monitoring system in the domestic market with a MARD value of less than 9%. Relying on the continuous, comprehensive, real-time and reliable all-day blood glucose information provided by silicon-based dynamic CGM, the digital blood glucose management solution has become a bridge connecting patients, their families and hospitals, effectively solving the problem of "information island" for diabetic patients, providing more refined management for diabetic patients, and finally realizing a new digital and intelligent closed-loop and hospital-wide continuous blood glucose management. It is understood that up to now, silicon-based dynamic CGM has been applied in nearly 1,500 hospitals above the second level, and through the digital management of diabetes, it has broken the multiple communication barriers between inside and outside the hospital, between departments in the hospital, between doctors and patients outside the hospital, and between patients and their families, helping the hospital to build a full-scene diabetes management ecology and realizing the efficient and refined management of diabetes patients.
Schematic diagram of full-scenario closed-loop management of diabetes).
Dr. Peng Can said that silicon-based bionic will continue to devote itself to the application and innovative research and development of "full closed-loop artificial pancreas", explore new reliable technologies and methods, improve the performance and safety of artificial pancreas, provide more accurate, safe and effective means for diabetic patients, and work with industry peers to jointly promote the development of diabetes prevention and treatment and metabolic disease diagnosis and treatment.
Disclaimer: The content of this article is this *** corporate information, which only represents the author's personal views and has nothing to do with this website. The content involved does not constitute investment and consumption advice, and is for readers' reference only, please verify the relevant content by yourself.
Original text**: Xianning News Network.